Recently, Haoyayi Group, a domestic oral healthcare enterprise, announced that its core strategic product, the Hanzu Implant, has successfully completed a Series C+ financing round totaling several tens of millions of RMB. This round was led by Anhui Chuanggu Capital. The proceeds will be primarily allocated to three key areas: deepening the technological iteration of domestic implants, accelerating R&D in digital implant equipment and novel biomaterials, and expanding production capacity to meet the market demand unleashed by the national centralized procurement program.

The Hanzu Implant, a flagship product under Haoyayi Group, adopts the world's fourth‑generation mainstream implant design philosophy and is co‑developed by senior European experts and leading Chinese clinicians, with independent intellectual property rights. Its design is tailored to the alveolar bone physiological characteristics of the Asian population, featuring rapid early osseointegration, support for immediate implantation and full‑arch restorations, and a clinical implant success rate exceeding 99%. Since being selected in the first round of the national centralized procurement for dental implant systems in 2023, the product has garnered significant attention from dental practitioners and patients alike.